OCUMETICS Aktie

 

Key Highlights   Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world.  Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts.  Calgary, Canada – TheNewswire - April 1, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, announced today that its leadership team will meet in Washington, D.C. with several potential ophthalmic strategic partners and leading industry stakeholders during the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The team will provide updates on the Company's First-in-Human (FIH) clinical program and outline the next phase of its clinical development strategy. During these meetings, Ocumetics will present the latest results from its ongoing...

  Key Highlights   Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durability, and manufacturability of the lens.  Enhanced Performance with Greater Reliability: This next-generation technology is anticipated to deliver natural optical responsiveness and improved mechanical stability, supporting excellent vision across its full range of focus.  German Engineering Collaboration Drives Precision: Partnership with a leading German manufacturing group is expected to enable tighter tolerances, efficient production-ready designs and exceptional quality output.  Accelerated Path to Commercialization: Streamlined design is expected to reduce testing complexity and regulatory management, and shorten development cycles that support scalable manufacturing.  Strengthened Competitive Position in Vision Restoration: This advancement differentiates Ocumetics as an authentic innovator, mo...

Calgary, Alberta – March 13, 2026 – TheNewswire -  Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) (the “Corporation”) announces that it has issued 500,000 incentive stock options to Howard Group Inc. “(Howard Group”), the Corporation's investor relations communications advisor, as required by the agreement between the Corporation and Howard Group announced on September 12, 2025.     Each option entitles Howard Group to purchase one common share in the capital of the Corporation at an exercise price per common share of $0.42 for a period of two years, which options shall vest quarterly in equal instalments over twelve months.  The stock options are not transferrable.  The common shares issued upon exercise of the stock options will be subject to a four-month resale restriction from the date of grant. About Ocumetics Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing adv...

   Calgary, Alberta – TheNewswire - February 26, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced the formation of a Scientific Advisory Committee (SAC) to support the Company's advancing clinical, regulatory, and commercialization strategy as it progresses toward late-stage development. The SAC will provide independent, multidisciplinary expertise across clinical trial design, regulatory strategy, surgical application, lens science, and translational research, ensuring strong clinical governance and informed decision making as Ocumetics prepares for pivotal clinical studies and future FDA engagement. The SAC will include Dr Ron Krueger, MD, MSE, a globally recognized ophthalmologist, surgeon, and innovator in refractive and cataract surgery. Dr. Krueger brings decades of leadership in clinical research, surgical innovation, and technology translation, including extensi...

  Calgary, Alberta – TheNewswire - February 24, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Raymond Marks has been appointed to its Board of Directors. Raymond Marks was instrumental in the early fundraising efforts of the Company and participated in meetings that resulted in Ocumetics securing financing for its initial public listing by reverse takeover. He has over 50 years of experience as an entrepreneur, owner, operator and manager across a variety of industries including the resources and industrial sectors. Throughout his career, Mr. Marks has worked with many such companies and has worked with growing companies to secure millions in financing for their strategic initiatives. Mr. Marks previously co-founded Tudor Gold Corp. (TSXV:TUD) and served as executive Vice President, and a director of Tudor from February 2016 until October 2018. Mr. Marks la...

  Calgary, Alberta – February 10, 2026 – TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporation has entered into a forbearance agreement with the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press release dated January 30, 2026 ).  Pursuant to the forbearance agreement the debentureholders will forbear from demanding payment of the Debentures and from taking any steps to realize upon any security granted in respect of the Debentures until June 19, 2027 notwithstanding the maturity of the Debentures.     The Debentures have an aggregate face value principal amount of up to $4,000,000 (the “Principal”). The Debentures bear interest at rate of 18% per annum, compounded annually.  Subject to the forbearance, the Debentures will mature, and Principal and interest will be payable by the Corporation, on the d...

Key Highlights Positive First-in-Human Results: Three-month Group 1 data met or exceeded expectations for safety, lens delivery, and vision performance.  Major De-Risking Milestone: The study successfully validated the core technology and cleared the path to the next clinical phase.  Life-Changing Vision Improvements: Patients with severe vision loss experienced meaningful improvements in everyday vision.  Strong Forward Momentum: Planning for Group 2 surgeries is underway, with lens and delivery enhancements already in development.  High Confidence Going Forward: Management remains fully confident in the Ocumetics accommodating intraocular lens platform following these results.  Calgary, Alberta – February 3, 2026 – TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced positive three-month postoperative results from Group 1 patients in its first-in-human (FIH) ...

  Calgary, Alberta – January 30, 2026 – TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it is seeking approval from the TSX Venture Exchange (the “Exchange”) with respect to a forbearance agreement to be entered into between the Corporation and the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press releases dated May 15, 2024, May 23, 2024 and June 21, 2024).  Under the proposed forbearance agreement, it is proposed that the Debentureholders will forbear from demanding payment of the Debentures and from taking any steps to realize upon any security granted in respect of the Debentures until June 19, 2027 notwithstanding the maturity of the Debentures.     The Debentures have an aggregate face value principal amount of up to $4,000,000 (the “Principal”). The Debentures bear interest at rate of 18% per annum, compounded an...

  Calgary, Alberta – TheNewswire - January 9, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced that it intends to form a Scientific Advisory Committee (SAC) to fill the role now being performed by a single Chief Medical Officer.  In the result, the consulting agreement with the Corporation's current Chief Medical Officer, Dr. Doyle Stulting, will terminate following a ninety-day transition period. As Ocumetics advances toward completion of its First-in-Human (FIH) study and prepares for a pivotal FDA clinical trial anticipated in 2027, the Company is evolving its medical and clinical leadership structure to align with its next exciting phase of growth and execution. The transition is from a single CMO structure to a broader multi-member Scientific Advisory Committee (SAC) structure. This committee will provide deeper and more diverse medical, clinical, and regulatory over...

    Calgary, AB – TheNewswire - January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has closed the first tranche of its previously announced best efforts brokered private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately $788,380 (the “Brokered Offering”). The Company is also pleased to announce the closing of a concurrent non-brokered private placement of Units for additional gross proceeds of approximately $235,450 (the “Non-Brokered Offering” and together with the Brokered Offering, the “Offerings”).   The Offerings were led by Centurion One Capital Corp. as lead agent and sole bookrunner (the “Lead Agent”) in respect of the Brokered Offering and fiscal advisor in respect of the Non-Brokered Offering. Tingle Merrett LLP acted as counsel to the Company, and Cassels Brock & Blackwell LLP acted as counsel to the Lead Agent in c...

  Calgary, AB – TheNewswire - December 19, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announced (November 25, 2025) brokered private placement (the “Offering”) on a best-efforts basis led by Centurion One Capital Corp. (the “Lead Agent”), the Corporation has amended the terms of the Offering.   Pursuant to the amended terms, up to 4,166,666 units of the Corporation (“Units”) will now be issued at an amended issue price of $0.60 per Unit (the “Amended Issue Price”) for aggregate gross proceeds of up to $2,500,000. Each Unit shall consist of one common share in the capital of the Corporation (each, a “Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one common share of the Corporation (each, a “Warrant Share”) at an exercise price of $0.75 per Warrant Share at any time for a period of thr...

  Calgary, Alberta – TheNewswire - December 9, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to surgeon input following first-in-human lens implantation procedures.   “The surgeon who performed our first-in-human implantations has been instrumental in shaping further improvements in the design of our lens delivery system that will be invaluable as we work to optimize the final configuration of the Ocumetics Lens,” said Dean Burns, President and CEO of Ocumetics.  “Medicel's willingness to innovate rapidly and refine their delivery platform for the Ocumetics Lens based on surgeon feedback demonstrates the strength of our partnership and Medicel's commitment to supporting next generation accommodating intrao...

  NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES   Calgary, AB – TheNewswire - November 25, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that it has entered into an agreement with Centurion One Capital Corp. (the “Lead Agent”) as lead agent and sole bookrunner, in connection with a brokered private placement to raise up to $2,500,000 (the “Offering“) through the sale of up to 3,472,222 units of the Corporation (“Units“) at an issue price of $0.72 per Unit (the “Issue Price”) on a best efforts basis. Each Unit shall consist of one common share in the capital of the Corporation (each, a “Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one common share of the Corporation (each, a “Warrant Share”) at a price of $0.90 per Warrant Share at any time for a period ...

Calgary, Alberta – TheNewswire - November 5, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).   Ocumetics completed Group 1 surgeries in August 2025 (“Day 1”) and completed additional Group 1 surgeries in September 2025 (“Day 2”). All Group 1 patients (Day 1 and Day 2) have now completed their one-month postoperative exams, showing Corrected Distance Visual Acuity (CDVA) ranging from 20/32 to 20/25. Click Image To View Full Size “We are thrilled by the visual outcomes we're seeing in our first group of patients,” said Dean Burns, President and CEO of Ocumetics. “These results have met, and in some cases, exceeded internal expectations at this early stage of recovery. Every Group 1 ...

Calgary, Alberta – TheNewswire - November 5, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).   Ocumetics completed Group 1 surgeries in August 2025 (“Day 1”) and completed additional Group 1 surgeries in September 2025 (“Day 2”). All Group 1 patients (Day 1 and Day 2) have now completed their one-month postoperative exams, showing Corrected Distance Visual Acuity (CDVA) ranging from 20/32 to 20/25. Click Image To View Full Size “We are thrilled by the visual outcomes we're seeing in our first group of patients,” said Dean Burns, President and CEO of Ocumetics. “These results have met, and in some cases, exceeded internal expectations at this early stage of recovery. Every Group 1 ...

    Calgary, Alberta – TheNewswire - October 24, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce it will be presenting at the Centurion One Capital 3rd Annual Bahamas Summit, a two day invitation only event taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 28th to Wednesday, October 29th, 2025, in Nassau, Bahamas.   Dean Burns, President and CEO of Ocumetics, will be presenting, attending investor meetings and participating in a panel discussion at the event.   “I am very excited to present our progress with the Ocumetics Accommodating Intraocular Lens and recent first-in-human study results with potential investors at the event,” said Dean Burns, President and CEO of Ocumetics.   For more information and registration details, please visit: www.centuriononecapital.com/bahamas-summit. About Ocumetics Ocumetics Technology Corp. (TSXV: OTC...

Calgary, Alberta – October 21, 2025 – TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel, NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.     Dean Burns, President and CEO of Ocumetics, will be participating in a panel titled 'A vision of Innovation' and moderated by Maxim Research Analysts.  In addition, Ocumetics will be meeting with institutional investors in a one-on-one format during the event.   Keynote speakers include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from small- and mid-cap companies, moderated by Max...

  Calgary, Alberta – TheNewswire - October 15, 2025.  Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) (the “Corporation”) announces that it has issued 732,000 incentive stock options to its directors.  Each option entitles the holder to purchase one common share in the capital of the Corporation at an exercise price per common share of $1.16 for a period of five years, vesting immediately.     The stock options are not transferrable.  The common shares issued upon exercise of the stock options will be subject to a four-month resale restriction from the date of grant. About Ocumetics Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhan...

    Calgary, Alberta – TheNewswire - October 14, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it is holding a webinar to discuss the one-month patient results for its initial Group 1 patients that received the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).   Webinar details are as follows:   Date: Thursday, October 15, 2025 Time: 6:00 PM ET   Join Ocumetics Director and CEO, Dean Burns, for an exclusive webinar covering important updates on our first-in-human (“FIH”) study and what lies ahead.   Topics will include: 1. Discussion of one-month postoperative patient results and observations from the FIH study 2. Next steps to complete the Ocumetics FIH study 3. Live Q&A session with Dean Burns   This is a timely opportunity to gain insight into Ocumetics' progress at this critical stage of development.   Reserve your spot now ...

  Calgary, Alberta – TheNewswire - October 8, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to report encouraging one-month safety and vision performance results for the first Group 1 patients that received the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).   “This again is a historic milestone for Ocumetics and for ophthalmology as a whole,” said Dean Burns, President and CEO of Ocumetics Technology Corp. “The safety profile and visual outcomes we're seeing at this early stage are what we hoped for, and we are excited to continue building momentum as the clinical trial progresses. These early outcomes highlight the transformative potential of the Ocumetics Lens and provide a strong foundation for continued clinical progress.”   “The early results are very exciting,” said Dr. Doyle Stulting, Chief Medical Officer of Ocumetics. “After one-month,...